Answers are grounded in this paper and cite their sources.
Result: Group A had 78 patients, group B 74 patients and group C 75 patients. Analysis of variance showed that the efficacy of the treatment differed significantly (F= 53.34, df1= 2, df2= 207, p-Value<0.001). The result of the post-hoc tests showed Synvisc Injection was the most effective showing significant improvement than both Osteonil Injection (mean diff=7.68, p<0.001, CI=4.73, 10.64) and Durolane Injection (mean diff=15.61, p<0.001, CI=12.63, 18.59). Osteonil Injection was found to be superior to Durolane Injection (mean diff=7.93, p<0.001, CI=10.89725, 4.957825). Conclusion: Viscosupplement (VS) agents provide significant though temporary symptomatic relief in grade 2 and 3 OA. The efficacy of all three agents was similar with marginal superiority of one over the other. Considering excellent tolerability, viscosupplementation may be included in the armamentarium of OA.
No takes yet. Share an insight, caveat, or question.
Alomran et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: